Applications of (R)-(-)-5-Oxotetrahydrofuran-2-Carboxylic Acid in Industrial Manufacturing

(R)-(-)-5-Oxotetrahydrofuran-2-Carboxylic Acid serves specialized roles across high-value industries due to its precise stereochemistry and reactive lactone structure. As the direct manufacturer, we support formulators and process engineers with reliable upstream supply for demanding downstream synthesis routes.

1. Pharmaceutical API Chiral Intermediate Synthesis

This acid is a key chiral building block in the production of several active pharmaceutical ingredients (APIs), especially within antiretroviral and central nervous system drug classes. Production processes deploy this acid in multi-step asymmetric synthesis where stereospecificity is critical. Application often centers on lactam- or pyrrolidinone-containing scaffolds. Production teams employ it during early- to intermediate-stage coupling and cyclization sequences, ensuring downstream purity and enantiomeric excess meet regulatory expectations.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP / EP / JP monographs (depending on API target)
• FDA 21 CFR Part 211 for finished pharmaceuticals
• REACH Annex XVII for handling and residuals

Typical usage ratio

• 0.15–0.40 molar equivalents relative to target scaffold per batch; adjusted according to step yield and impurity profile.

Downstream process integration

• Direct addition to enantioselective coupling reactors following catalyst charging
• Introduced after preliminary protection/deprotection sequences
• Neutralization and downstream extraction via aqueous-organic interfaces before next synthetic block

Final product types

• API intermediates (e.g., chiral pyrrolidinone derivatives for antiepileptic drugs)
• Final API forms after multi-step elaboration
• Stereo-controlled scaffolds for CNS and antiviral drugs

2. Peptide and Peptidomimetic Structure Modification

Peptide manufacturers use (R)-(-)-5-Oxotetrahydrofuran-2-Carboxylic Acid as a conformational constraint element. Its structure facilitates the cyclization of linear peptides or integration as a rigid analog in peptidomimetics. Researchers incorporate it to induce turn motifs or enhance metabolic stability in peptide-based products, often performing coupling via carbodiimide chemistry or activating esters under controlled conditions.

Industry compliance standards

• ISO 13485 for medical-grade peptide production
• FDA QSR 21 CFR 820 for bioactive peptide devices
• USP <1047> on peptide and polypeptide drug quality
• GMP guidance for investigational new drugs (IND)

Typical usage ratio

• 1–6 mol% relative to the total amino acid content, depending on desired rigidity and the sequence design

Downstream process integration

• Introduced during solid-phase peptide synthesis or solution-phase cyclization
• Activated prior to coupling with protected peptides via HATU or EDC reagents
• Integrated just before terminal truncation or resin cleavage step

Final product types

• Peptide-based research reagents
• Therapeutic peptidomimetics with constrained backbones
• Diagnostic polypeptide analogs

3. Fine Chemical Synthesis for Agrochemical Active Ingredients

Key crop protection manufacturers utilize this carboxylic acid in the synthesis of enantio-enriched intermediates for potent agrochemicals, especially in the preparation of chiral heterocycles and lactam-based insecticides or fungicides. Application generally occurs during mid-stage process development where regio- and stereocontrol are critical for field performance and regulatory approvals.

Industry compliance standards

• FAO/WHO Specifications for pesticides (JMPS/WHO)
• EPA 40 CFR 158: Pesticide Data Requirements
• ISO 9001 for technical grade production
• REACH substance registration for chemical safety

Typical usage ratio

• 2–10% w/w in total reaction mass, calibrated to batch size and targeted chiral intermediate complexity

Downstream process integration

• Fed into continuous-flow reactors after pre-catalyst introduction
• Used in high-pressure or high-temperature cyclizations
• Isolated via solvent extraction before formulation into actives

Final product types

• Chiral pesticides and fungicides
• Intermediates for selective herbicides
• Advanced crop protection agents

4. Stereoselective Polymer Raw Material Modification

Specialty polymer and advanced material producers leverage this acid as a stereodefined modifier in the synthesis of polyamides or polyesters where mechanical and optical properties depend on chiral purity. It is introduced to impart asymmetric centers within the polymer backbone, supporting application areas such as biomedical scaffolds and optically active films. The monomer often reacts via melt or solution polycondensation under inert atmosphere for high-molecular-weight product formation.

Industry compliance standards

• ISO 10993-1 for medical device materials
• USP Class VI for biomedical polymers in contact with fluids
• ASTM D638 for mechanical testing of plastics
• ISO 9001 for quality management in specialty chemicals

Typical usage ratio

• 3–15 mol% relative to base monomer units to achieve target physical property modification and chirality

Downstream process integration

• Charged to reactor following diol/diamine addition in batch or fed-batch mode
• Polymerized under vacuum or nitrogen atmosphere at 160–210°C
• Chain-stopped before precipitation and pelletization

Final product types

• Implantable medical polymers
• Chiral optical films
• Functionalized engineering plastics

5. Asymmetric Catalysis Ligand & Auxiliary Preparation

Producers of chiral catalysts and ligands incorporate (R)-(-)-5-Oxotetrahydrofuran-2-Carboxylic Acid as a precursor to highly selective auxiliaries for use in asymmetric catalysis. The carboxyl and lactone functionalities enable straightforward conversion into tailored ligands that drive enantioselective transformations in pharmaceutical and specialty fine chemical synthesis. The acid is transformed through esterification, amidation, or ring-opening reactions under cleanroom conditions to prevent racemization or contamination effects on catalyst performance.

Industry compliance standards

• ISO 9001 for laboratory reagent production
• Responsible Care (RC14001) for environmental and process safety management
• Patent information disclosure requirements for catalyst commercialization
• Custom QC protocols for stereochemical analysis (chiral HPLC, NMR)

Typical usage ratio

• Varies from 0.3–1.2 equivalents in ligand synthesis, calculated based on targeted ligand backbone and scale of downstream batch catalysis; tightly controlled for chiral purity

Downstream process integration

• Initial substrate in ligand precursor synthesis prior to metal complexation
• Functional group manipulation in glovebox before final ligand assembly
• Integrated into catalyst precursor formulations for reaction screening and process scale-up

Final product types

• Enantioselective organometallic catalysts
• Chiral ligand libraries for high-throughput screening
• Auxiliaries used in industrial asymmetric hydrogenation or addition